• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚合物递送 siRNA 双重沉默 Mcl-1 和 P-糖蛋白并诱导耐药乳腺癌细胞凋亡。

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.

机构信息

Department of Chemical and Material Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta, Canada.

出版信息

Cancer Gene Ther. 2013 Mar;20(3):169-77. doi: 10.1038/cgt.2013.8. Epub 2013 Mar 1.

DOI:10.1038/cgt.2013.8
PMID:23449477
Abstract

Enhanced survival mechanisms of malignant cells in combination with elevated levels of drug transporters can sustain an undesirable resistance against drug therapy. Short interfering RNA (siRNA) delivery against targets involved in aberrant mechanisms is a promising approach and we hypothesize that simultaneous silencing of multiple targets could prove more advantageous than common approach to silence individual targets. To explore this approach, we targeted anti-apoptotic proteins myeloid cell leukemia 1 (Mcl-1) and survivin along with the efflux pump P-glycoprotein (P-gp) in drug-resistant breast cancer cells. Polymeric siRNA delivery was employed for this purpose by using small polyethylenimine (PEI) substituted with lipids. While silencing Mcl-1 caused ∼90% cell death in wild-type cells, this effect was less significant in P-gp over-expressing cells. An additive effect for Mcl-1 and P-gp silencing was evident in the latter cells, where simultaneous silencing of these targets created a significantly higher effect compared with silencing each individual target. Prolonged exposure of wild-type cells to doxorubicin (DOX) resulted in upregulation of P-gp, breast cancer resistance protein, survivin and Mcl-1. Dual silencing of P-gp and Mcl-1 again resulted in an additive effect in resistance-induced cells, which displayed an increased dependency on Mcl-1 for survival. Cytotoxic effect of DOX was also enhanced in resistance-induced cells after silencing Mcl-1. We conclude that polymer-mediated siRNA delivery can silence multiple targets simultaneously and reverse drug resistance.

摘要

恶性细胞增强的生存机制与药物转运体水平升高相结合,可以维持对药物治疗的不良耐药性。针对异常机制相关靶点的短干扰 RNA(siRNA)递送是一种很有前途的方法,我们假设同时沉默多个靶点可能比单独针对单个靶点的常见方法更有利。为了探索这种方法,我们针对耐药乳腺癌细胞中的抗凋亡蛋白髓样细胞白血病 1(Mcl-1)和生存素以及外排泵 P-糖蛋白(P-gp)。为此,我们使用带有脂质的小聚乙烯亚胺(PEI)来进行聚合物 siRNA 递送。虽然沉默 Mcl-1 会导致野生型细胞约 90%的细胞死亡,但在 P-gp 过表达的细胞中这种效果不那么明显。在后者的细胞中,Mcl-1 和 P-gp 沉默的协同作用是明显的,同时沉默这些靶点会产生比单独沉默每个靶点更高的效果。野生型细胞长时间暴露于阿霉素(DOX)会导致 P-gp、乳腺癌耐药蛋白、生存素和 Mcl-1 的上调。在耐药诱导的细胞中,P-gp 和 Mcl-1 的双重沉默再次产生协同作用,这些细胞对 Mcl-1 的生存依赖性增加。沉默 Mcl-1 后,耐药诱导细胞中 DOX 的细胞毒性作用也增强。我们得出结论,聚合物介导的 siRNA 递送可以同时沉默多个靶点并逆转耐药性。

相似文献

1
Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.聚合物递送 siRNA 双重沉默 Mcl-1 和 P-糖蛋白并诱导耐药乳腺癌细胞凋亡。
Cancer Gene Ther. 2013 Mar;20(3):169-77. doi: 10.1038/cgt.2013.8. Epub 2013 Mar 1.
2
Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.多柔比星可诱导乳腺癌细胞死亡,而与 Survivin 和 XIAP 的表达水平无关。
Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56. doi: 10.1016/j.ejcb.2013.08.001. Epub 2013 Aug 31.
3
Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.通过 siRNA 递送沉默survivin 诱导人乳腺癌细胞系凋亡。
Mol Pharm. 2011 Oct 3;8(5):1821-30. doi: 10.1021/mp200176v. Epub 2011 Aug 23.
4
Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.小干扰 RNA(siRNA)逆转多柔比星耐药 MCF-7 乳腺癌细胞的多药耐药性。
Biomed Pharmacother. 2011 Mar;65(2):85-9. doi: 10.1016/j.biopha.2010.12.007. Epub 2010 Dec 30.
5
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.曲妥珠单抗和拉帕替尼耐药的 HER2 阳性乳腺癌细胞丧失对 HER2 的依赖,并对多靶点激酶抑制剂索拉非尼敏感。
Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.
6
Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.多柔比星敏感和耐药乳腺癌细胞对联合 siRNA 治疗的有效反应。
J Control Release. 2013 Nov 28;172(1):219-228. doi: 10.1016/j.jconrel.2013.08.012. Epub 2013 Aug 30.
7
Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery.通过小干扰RNA递送使乳腺癌细胞对TRAIL诱导的凋亡敏感的新靶点。
Int J Cancer. 2018 Feb 1;142(3):597-606. doi: 10.1002/ijc.31079. Epub 2017 Oct 16.
8
Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat.多功能纳米载体介导的多西紫杉醇和 siRNA 的共递送协同增强大鼠胶质瘤细胞凋亡。
Biomaterials. 2012 Feb;33(4):1170-9. doi: 10.1016/j.biomaterials.2011.10.057. Epub 2011 Nov 5.
9
Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells.小干扰RNA沉默髓样细胞白血病-1可提高U-937白血病细胞对依托泊苷的化疗敏感性。
J Biol Regul Homeost Agents. 2016 Jan-Mar;30(1):55-65.
10
Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.预处理柔红霉素下调 Mcl-1 逆转乳腺癌细胞对 TNF 相关凋亡诱导配体的耐药性。
Biochem Biophys Res Commun. 2012 May 25;422(1):42-7. doi: 10.1016/j.bbrc.2012.04.093. Epub 2012 Apr 25.

引用本文的文献

1
siRNA and targeted delivery systems in breast cancer therapy.乳腺癌治疗中的小干扰RNA及靶向递送系统
Clin Transl Oncol. 2023 May;25(5):1167-1188. doi: 10.1007/s12094-022-03043-y. Epub 2022 Dec 23.
2
Understanding MCL1: from cellular function and regulation to pharmacological inhibition.理解 MCL1:从细胞功能和调控到药理学抑制。
FEBS J. 2022 Oct;289(20):6209-6234. doi: 10.1111/febs.16136. Epub 2021 Aug 2.
3
Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer.髓系细胞白血病-1是小细胞肺癌生存和进展的重要预测指标。
Ann Transl Med. 2020 Dec;8(23):1589. doi: 10.21037/atm-20-2305.
4
Prospects for RNAi Therapy of COVID-19.新冠病毒病的RNA干扰疗法前景
Front Bioeng Biotechnol. 2020 Jul 30;8:916. doi: 10.3389/fbioe.2020.00916. eCollection 2020.
5
Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models.使用随机逻辑模型识别癌症信号通路中的潜在药物靶点
Sci Rep. 2016 Mar 18;6:23078. doi: 10.1038/srep23078.
6
Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.小干扰RNA预暴露对后续小干扰RNA治疗反应的影响。
Pharm Res. 2015 Dec;32(12):3813-26. doi: 10.1007/s11095-015-1741-z. Epub 2015 Jul 1.
7
Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.利用脂质取代的聚亚乙基亚胺通过 siRNA 靶向乳腺癌细胞中的细胞周期蛋白。
Front Bioeng Biotechnol. 2015 Feb 16;3:14. doi: 10.3389/fbioe.2015.00014. eCollection 2015.
8
Expression of P-gp in acute myeloid leukemia and the reversal function of AsO on drug resistance.P-糖蛋白在急性髓系白血病中的表达及反义寡核苷酸对耐药的逆转作用
Oncol Lett. 2015 Jan;9(1):177-182. doi: 10.3892/ol.2014.2692. Epub 2014 Nov 10.
9
Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.玛瑞托司在Mcl-1表达升高的急性髓系白血病细胞中诱导凋亡。
Cancer Biol Ther. 2014 Aug;15(8):1077-86. doi: 10.4161/cbt.29186. Epub 2014 May 19.
10
Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.马法兰奥马西他明与阿霉素的脂质体共递送用于协同增强抗肿瘤活性。
Pharm Res. 2014 Aug;31(8):2178-85. doi: 10.1007/s11095-014-1317-3. Epub 2014 Feb 22.